• Takeda's TYK2 inhibitor shows promising phase 2 results in psoriasis

    4 days ago - By Healio

    NEW ORLEANS - Phase 2b clinical trial results of Takeda Pharmaceuticals' novel tyrosine kinase 2 inhibitor found significantly greater skin clearance in study patients compared with placebo, according to a presentation here.
    In the phase 2b, randomized, double-blind, placebo-controlled study, April W. Armstrong, MD, MPH, FAAD, professor of dermatology and associate dean for clinical research at Keck School of Medicine of the University of Southern California, and colleagues randomly assigned 259 patients to receive 2 mg, 5 mg, 15 mg or 30 mg of TAK-279 once
    Read more ...